The results of our study showed that there was no significant difference in bone marrow BCMA expression of MM patients with different types (P>0.05), which indicates that patients’ MM classification may not be the main factor that needs to be considered in the selection of suitable patients for BCMA CAR-T therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.